Pluri Inc.

pluri-biotech.com

Formerly Pluristem Therapeutics

High-Tech Company
Public Company

(Frankfurt Stock Exchange: PJT), (NASDAQ GM: PLUR), (TASE: PLUR)

TECH VERTICALS

AgriTech, Biologicals, Biotechnology, Cell Therapy, FoodTech, MedTech, Regenerative Medicine

General Data

Sector	Biomed
Company Stage:	Initial Revenues
Established	2001
Number of Employees	130
Reg. Number:	abCDe

DESCRIPTION

Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company's technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives—from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri's method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food-tech and agtech and biologics aims to establish partnerships that leverage the Company's 3D cell-based technology to additional industries that require effective, mass cell production. The company also offers CDMO services.

TECHNOLOGY

Cell Therapy, Biotechnology, Regenerative Medicine, FoodTech, AgTech, CDMO.

Products and Phases

Product	Phase
PLX-PAD	Phase III
PLX-PAD cells promote regeneration by releasing factors in response to tissue damage from trauma or inflammation. These factors activate repair mechanisms, support tissue renewal, and modulate immune-related inflammation. They also help rebalance the immune system, addressing autoimmune attacks on cells and organs. Pluri completed a global Phase III trial of PLX-PAD for muscle recovery post-hip fracture surgery. In 2023, an international consortium led by Charité Berlin, funded by EU Horizon Europe, plans a Phase I/II trial for Osteoarthritis (OA). Additionally, Tel Aviv Sourasky Medical Center is conducting a Phase I/II trial for treating steroid-refractory chronic graft-versus-host disease (cGvHD).
Placental MAIT Cells
CAR-T immunotherapy has shown monumental success in treating hematological malignancies, with the FDA approving six autologous CAR-T cell therapies to date. Despite revolutionary progress in hematological malignancies, equivalent success has yet to be duplicated in solid tumor malignancies which present unique challenges. Offering substantial benefits compared to conventional T cells, Pluri’s MAIT cells are isolated from human placentas, a source rich in highly potent allogeneic immune cells which is often overlooked in traditional therapies. These cells express high levels of various chemokine receptors, which facilitate their migration directly to tumor sites. Furthermore, unlike conventional T cells typically collected from peripheral blood, Pluri’s MAIT cells demonstrate a lower alloreactivity profile. This characteristic not only minimizes their likelihood of inducing Graft versus Host Disease (GvHD) – a significant advantage over other potential allogeneic products – but also suggests that they may persist in the body for a longer duration, enhancing their therapeutic efficacy.
PLX-R18	Phase III
PLX-R18 cells release a combination of therapeutic proteins in response to a damaged or poorly functioning hematopoietic system; this system creates the blood cells that protect us from infection, uncontrolled bleeding and anemia. The product is currently in development to treat poor graft function following hematopoietic cell transplantation and Acute Radiation Syndrome (ARS). PLX-R18 cell therapy was granted an orphan drug designation by the FDA for the treatment of ARS.

ESTIMATED ANNUAL SALES

	TARGET MARKETS
	Inflammation, Osteoarthritis, hematological disorders, radiation damage, FoodTech, Cultivated Meat, Fish, Dairy, Coffee, Cacao, AgTech.

	BUSINESS MODEL
	B2B

AFFILIATION

Account ID	Affiliation Type	Name	Parent Name	Status
64CB77DE-1F7A-E111-AC59-00155D32A403		Pluri Inc.
6BB5EE8F-B672-EC11-B80D-00505695CD29	Subsidiary	Ever After Foods Ltd.	Pluri Inc.
487A1C49-0233-EF11-B815-00505695CD29	Spin-off	Coffeesai Ltd.	Pluri Inc.

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Law Firm
abC Defghij	Accounting Firm

REMARKS

Date	Remark
	All of Pluri's subsidiaries are listed directly under Pluri Biotech Ltd., which is a subsidiary of Pluri Inc.

CONTACT INFO

Expand / Collapse All

Main Address: Haifa, Israel

Address	MATAM Advanced Technology Park Building #5
City	Haifa
Country	Israel
Zip	3508409

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Germany

Country	Germany

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: United States

Country	United States

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Yaky Yanay	CEO & President	EVS (VP & CFO)
Mr. Lior Raviv	CTO
Ms. Liat Zalts	CFO	Matics (CFO)
Ms. Efrat Kaduri	Chief Business Development Officer – Pharma
Dr. Michal Sheleg	VP, Clinical Development
Dr. Arthur Machlenkin	CSO	Pantheon Biosciences (CEO)
Mr. Nimrod Bar-Zvi	Chief Commercial Officer
Ms. Efrat Livne-Hadass	Chief Wellbeing Officer
Ms. Maggie Ben-Gad	Public Relations Manager
Mr. Yoram Drucker	Co-Founder	IR-MED (VP, Business Development & Chairman)
Dr. Shai Meretzki	Co-Founder	Pluri (CEO)

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Executive Chairman	Founder, VLScom Ltd.
abC Defghij	Board Member	President, Co-CEO, Pluri
abC Defghij	Board Member	CEO, Doron Birger Management and Consulting
abC Defghij	Board Member	Founder & President, Catalyst Group International LLC
abC Defghij	Board Member	Chief Commercial Officer, Octave Bioscience Inc.
abC Defghij	Board Member	Private Investor

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Reverse Merger

May. 05, 2003

abCDe

Reverse merger with the shell company A.I. Software; Originaly traded under ticker PLRS.OB. Ticker changed on 11/2007 after advancing to NASDAQ Capital Market.

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Other	abCDe

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Feb. 04, 2021	Ninth Public Offering	NASDAQ GM	abCDe	abCDe	Registered Direct Offering
May. 05, 2020	Eighth Public Offering	NASDAQ CM	abCDe	abCDe	Registered Direct Offering.
Apr. 08, 2019	Seventh Public Offering	NASDAQ CM	abCDe	abCDe
Oct. 30, 2017	Sixth Public Offering	TASE	abCDe	abCDe
Jan. 25, 2017	Fifth Public Offering	NASDAQ CM	abCDe	abCDe
Jun. 28, 2015	Fourth Public Offering	NASDAQ CM	abCDe	abCDe
Sep. 19, 2012	Third Public Offering	NASDAQ CM	abCDe	abCDe
Jan. 27, 2011	Second Public Offering	NASDAQ CM	abCDe	abCDe	Including Green Shoe option of $5.3m
Dec. 19, 2010	Dual Listing	TASE	abCDe	abCDe
Dec. 10, 2007	Listing	NASDAQ CM	abCDe	abCDe
May. 09, 2007	Listing	Frankfurt Stock Exchange	abCDe	abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Feb. 04, 2025

Initial Revenues

abCDe

PIPE

Jan. 23, 2025

Initial Revenues

abCDe

PIPE

Dec. 15, 2022

Initial Revenues

abCDe

PIPE

Dec. 17, 2013

R&D

abCDe

PIPE

Oct. 12, 2010

R&D

abCDe

PIPE

Apr. 28, 2010

R&D

abCDe

PIPE

Oct. 12, 2009

R&D

abCDe

PIPE

May. 06, 2009

R&D

abCDe

PIPE

Dec. 03, 2008

R&D

abCDe

PIPE

Sep. 23, 2008

R&D

abCDe

PIPE

Aug. 06, 2008

R&D

abCDe

PIPE - Extended

May. 22, 2007

R&D

abCDe

PIPE

Feb. 14, 2007

R&D

abCDe

PIPE

Apr. 05, 2006

R&D

abCDe

PIPE - Extended

Mar. 07, 2005

R&D

abCDe

PIPE

Jan. 27, 2005

R&D

abCDe

PIPE

Jan. 20, 2004

R&D

abCDe

Seed

Oct. 01, 2002

Seed

abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Jun. 01, 2024

Initial Revenues

abCDe

R&D Grant

Sep. 06, 2017

R&D

abCDe

R&D Grant

Dec. 27, 2016

R&D

abCDe

In collaboration with the New York Blood Center (NYBC).

R&D Grant

Jun. 17, 2015

R&D

abCDe

R&D Grant

Apr. 30, 2014

R&D

abCDe

R&D Grant

Aug. 06, 2013

R&D

abCDe

R&D Grant

Apr. 30, 2012

abCDe

R&D Grant

Jan. 18, 2012

abCDe

R&D Grant

Aug. 30, 2010

abCDe

R&D Grant

Jun. 28, 2010

abCDe

R&D Grant

Jun. 29, 2009

abCDe

R&D Grant

Dec. 08, 2008

abCDe

R&D Grant

May. 31, 2007

abCDe

R&D Grant

Oct. 18, 2006

abCDe

	Acquisitions made by Pluri

Acquired Company	Sector	Date	Amount	Remarks
abC Defghij	Hardwa...	Jan. 23, 2025	abCDe	In Stock. Holds 71% of the company.

	PORTFOLIO COMPANIES

Current Portfolio Companies (1)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

Ever After Foods

Agri

First Round

18/06/2024

N/A

$10m

Last Updated:	abCDe
IVC Number:	abCDe